Ann: American Assoc for Cancer accepts Late-Breaking Abstract, page-35

I agree with the long term sentiment but I have to disagree on the shareprice in the coming 12 months.

Of course the company won't be making profits in the coming 12 months but with successful canine and human trials phase 1/2, which I think are highly possible on the results thus far, I think the potential of the company will take it far beyond a 10 mill market cap.

We have the deals with two seperate pharmas for the human and canine side of PPl-1 which can/will be commercialised quite quickly if all things go to plan. The potential alone in this company is worth a considerate amount more than current valuation (in my opinion of course) and having epichem growing revenues and profits is somewhat of a safeguard.